Rocket Pharmaceuticals (RCKT) Accumulated Depreciation (2014 - 2026)

Rocket Pharmaceuticals has reported Accumulated Depreciation for 13 years, with the latest figure at $30.7 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 29.64% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.7 million (up 29.64% YoY) and the FY2025 annual result came in at $29.1 million, up 37.03% from the prior year.
• Accumulated Depreciation advanced to $30.7 million in Q1 2026 per RCKT's latest filing, from $29.1 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $30.7 million in Q1 2026 and troughed at $6.0 million in Q1 2022.
• A 5-year average of $17.0 million and a median of $15.7 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation surged 120.11% in 2022, then gained 29.64% in 2026.
• Over 5 years, Accumulated Depreciation stood at $9.1 million in 2022, then surged by 54.32% to $14.0 million in 2023, then soared by 51.46% to $21.3 million in 2024, then soared by 37.03% to $29.1 million in 2025, then increased by 5.52% to $30.7 million in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $30.7 million, $29.1 million, and $27.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.